我国抗肿瘤药物市场现状及发展趋势研究  

Marketing status and potential analysis for antineoplastic angents

作　　者：陈海燕[1] 马爱霞[1] 陈在余[1] 

机构地区：[1]中国药科大学国际医药商学院,南京210009

出　　处：《北方药学》2012年第11期51-52,共2页Journal of North Pharmacy

摘　　要：目的:本文旨在探究目前抗肿瘤药物的市场现状和各类药物发展趋势如何。方法:通过对全国16个重点城市的抗肿瘤医院总体用药情况进行市场份额、增长率、各类别抗肿瘤药物市场份额、各品种抗肿瘤药物市场份额等方面进行分析,并具体结合2009～2010年间各类别和各品种抗肿瘤药物市场情况进行趋势分析。结果:从抗肿瘤药物市场总体情况分析可以看出,整体呈现稳步增长的趋势,各类别之间市场份额显现出了四分天下的局面。结论:各类别间免疫抑制剂市场份额占据最大,其他类中以单抗类、铂类等药物位于其次,植物类药物位于季军;品种中以胸腺五肽最具有竞争优势,市场份额达到了5.32%,且销售额增长率高达30.37%。Objective：This article aims to explore the brand drugs which are the main and potential medications effective in the current anticancer drags market. Methods：Through analysis of the market share of the Antineoplastic Agents and its growth rate, which are mainly used in the Antineoplastic Agents of the sixteen key cities all over the country, as well as analysis of the growth rate of the sub-brand drugs and the brand leader and their market shares. With the above analysis combined with the investigation of the potential of the brand-name drugs and the sub-brand drugs inhabiting growth of tumor between 2009 and 2010. Results：Through above reveal that the market overall shows a steady growth and that among each of the categories＇markets, the market shares show a quarter of the world situation. Conclusion：All kinds of sub-inmmnosuppressive agents are the brand leader following with other oxaliplatin,and monoclonal antibody drugs which rank above plant-based drugs. Among the brand-name drugs, thymopentin possesses the enormous sales potential with the market share to 5.32% and the sales growth rate up to 30.37%.

关 键 词：抗肿瘤药物 市场现状 

分 类 号：R979.1[医药卫生—药品]